Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spectral Medical ( (TSE:EDT) ) has shared an announcement.
Spectral Medical announced its financial results for the fourth quarter and fiscal year 2024, highlighting significant clinical and operational progress. The company is nearing full enrollment in its Phase III Tigris trial, which evaluates PMX for endotoxic septic shock, and is working towards FDA submission. Despite challenges such as Hurricane Helene impacting the medical supply chain, enrollment has been robust, with 154 patients enrolled to date. Spectral is also collaborating with Vantive on commercialization plans, anticipating a positive trial outcome and preparing for PMX’s market launch. The completion of the Tigris study and the PrisMax sub-study are key milestones that could enhance Spectral’s industry positioning and stakeholder value.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company is primarily involved in clinical trials and commercialization efforts for its PMX treatment, targeting the reduction of mortality rates associated with septic shock. Spectral collaborates with partners like Vantive US Healthcare LLC to enhance its market presence and operational capabilities.
YTD Price Performance: 41.62%
Average Trading Volume: 13,582
Technical Sentiment Signal: Sell
Current Market Cap: $147.6M
See more insights into EDT stock on TipRanks’ Stock Analysis page.